Literature DB >> 20662734

Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers.

Helene Skjøt-Arkil1, Natasha Barascuk, Thomas Register, Morten A Karsdal.   

Abstract

Worldwide, cardiovascular disease (CVD) is the leading cause of death. Most CVD-related deaths are caused by years of preceding atherogenesis and the extensive development of atherosclerotic plaques, some of which may rupture to cause myocardial infarction. Macrophages are known to have a role in almost all stages of atherosclerosis, by both initiating atherosclerotic plaques and degrading them through the secretion of proteolytic enzymes leading to rupture. This review summarizes the literature on the role of macrophages and their proteolytic activity on proteins in the extracellular matrix (ECM) of the atherosclerotic plaque with a view to suggest a novel approach for identification of vulnerable plaques and turnover by the use of a new type of biomarker. The PubMed database was searched using the terms macrophages, foam cells, atherosclerosis, CVD, ECM remodeling, biomarker, neoepitope, matrix metalloproteinase (MMP), and protease. Atherosclerotic plaques are primarily composed of the protein type I and III collagen, and smaller quantities of elastin and proteoglycans. Macrophages secrete an array of proteases, including MMPs, cathepsins, and aggrecanases, with the ability to degrade most of the constituents of the ECM of the atherosclerotic plaque. At present it is not clear which proteases play pivotal roles at distinct stages of pathogenesis, rather that the combined proteolytic potential with some proteases at early stages and other at later stages may result in plaque rupture. This macrophage-mediated proteolysis and remodeling of the ECM play important roles in many stages of atherosclerosis. The degradation fragments of these ECM events are specific neoepitopes, which are released into the circulation. The identification of these pathologically relevant neoepitopes leads to novel biomarkers able to identify the formation and degradation of plaques providing different biological information than traditionally used biomarkers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662734     DOI: 10.1089/adt.2009.0258

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  13 in total

Review 1.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

2.  Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.

Authors:  Xiang Guo; Brandon W Higgs; Anne C Bay-Jensen; Morten A Karsdal; Yihong Yao; Lorin K Roskos; Wendy I White
Journal:  J Invest Dermatol       Date:  2015-05-20       Impact factor: 8.551

3.  Differential response of arterial and venous endothelial cells to extracellular matrix is modulated by oxygen.

Authors:  Luciana Lassance; Heidi Miedl; Viktoria Konya; Akos Heinemann; Birgit Ebner; Hubert Hackl; Gernot Desoye; Ursula Hiden
Journal:  Histochem Cell Biol       Date:  2012-02-01       Impact factor: 4.304

Review 4.  Inflammation and immune system interactions in atherosclerosis.

Authors:  Bart Legein; Lieve Temmerman; Erik A L Biessen; Esther Lutgens
Journal:  Cell Mol Life Sci       Date:  2013-02-21       Impact factor: 9.261

5.  Differential effects of estradiol on carotid artery inflammation when administered early versus late after surgical menopause.

Authors:  Areepan Sophonsritsuk; Susan E Appt; Thomas B Clarkson; Carol A Shively; Mark A Espeland; Thomas C Register
Journal:  Menopause       Date:  2013-05       Impact factor: 2.953

6.  Atherofibrosis - a unique and common process of the disease pathogenesis of atherosclerosis and fibrosis - lessons for biomarker development.

Authors:  Efstathios Vassiliadis; Natasha Barascuk; Morten A Karsdal
Journal:  Am J Transl Res       Date:  2013-01-21       Impact factor: 4.060

7.  Identification of an Endogenously Generated Cryptic Collagen Epitope (XL313) That May Selectively Regulate Angiogenesis by an Integrin Yes-associated Protein (YAP) Mechano-transduction Pathway.

Authors:  Jacquelyn J Ames; Liangru Contois; Jennifer M Caron; Eric Tweedie; Xuehui Yang; Robert Friesel; Calvin Vary; Peter C Brooks
Journal:  J Biol Chem       Date:  2015-12-14       Impact factor: 5.157

Review 8.  Macrophage differentiation and function in atherosclerosis: opportunities for therapeutic intervention?

Authors:  Howell J Williams; Edward A Fisher; David R Greaves
Journal:  J Innate Immun       Date:  2012-04-27       Impact factor: 7.349

9.  Acute Myocardial Infarction and Pulmonary Diseases Result in Two Different Degradation Profiles of Elastin as Quantified by Two Novel ELISAs.

Authors:  Helene Skjøt-Arkil; Rikke E Clausen; Lars M Rasmussen; Wanchun Wang; Yaguo Wang; Qinlong Zheng; Hans Mickley; Lotte Saaby; Axel C P Diederichsen; Jess Lambrechtsen; Fernando J Martinez; Cory M Hogaboam; Meilan Han; Martin R Larsen; Arkadiusz Nawrocki; Ben Vainer; Dorrit Krustrup; Marina Bjørling-Poulsen; Morten A Karsdal; Diana J Leeming
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

10.  Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation.

Authors:  Helene Skjøt-Arkil; Rikke E Clausen; Quoc Hai Trieu Nguyen; Yaguo Wang; Qinlong Zheng; Fernando J Martinez; Cory M Hogaboam; Meilan Han; Lloyd B Klickstein; Martin R Larsen; Arkadiusz Nawrocki; Diana J Leeming; Morten A Karsdal
Journal:  BMC Pulm Med       Date:  2012-07-20       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.